Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase

British Journal of Cancer

Volumn 106, Issue 2, 2012, Pages 324-332

  Kelly, M P ^a   Jungbluth, A A ^a   Wu, B W ^b   Bomalaski, J ^b   Old, L J ^a   Ritter, G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Polaris Group   (United States)

Author keywords

arginine deiminase; argininosuccinate synthetase; autophagy; in vivo; SCLC

Indexed keywords

ARGININE DEIMINASE; ARGININE DEIMINASE PEG20; ARGININOSUCCINATE SYNTHASE; CASPASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; AUXOTROPHY; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; TUMOR XENOGRAFT; WESTERN BLOTTING;

ARGININOSUCCINATE SYNTHASE; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA PRIMERS; GENE SILENCING; HUMANS; HYDROLASES; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SMALL CELL LUNG CARCINOMA;

EID: 84856458783     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.524     Document Type: Article

References (43)

1. Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Melucci MT, Ensor CM, Prestayko AW, Holtsberg FW, Bomalaski JS, Clark MA, Savaraj N, Feun LG, Logan TF (2005) Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 23(30): 7660-7668 (Pubitemid 46291831)
2. Bowles TL, Kim R, Galante J, Parsons CM, Virudachalam S, Kung HJ, Bold RJ (2008) Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer 123(8): 1950-1955
3. Bursch W, Karwan A, Mayer M, Dornetshuber J, Frohwein U, Schulte-Hermann R, Fazi B, Di Sano F, Piredda L, Piacentini M, Petrovski G, Fesus L, Gerner C (2008) Cell death and autophagy: cytokines, drugs, and nutritional factors. Toxicology 254(3): 147-157
4. Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, Szlosarek PW (2010) Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 126(12): 2762-2772
5. Delman KA, Brown TD, Thomas M, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA, Curley SA (2005) Phase I/II trial of pegylated arginine deiminase (ADI-PEG20) in unresectable hepatocellular carcinoma. J Clin Oncol (Meeting Abstracts) 23(16-suppl): 4139-413
6. Demedts IK, Vermaelen KY, van Meerbeeck JP (2010) Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J 35(1): 202-215
7. Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA (2004) Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 100(4): 826-833 (Pubitemid 38176863)
8. Dowell JE (2010) Small cell lung cancer: are we making progress? Am J Med Sci 339(1): 68-76
9. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA (2002) Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 62(19): 5443-5450
10. Feun L, Savaraj N (2006) Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs 15(7): 815-822
11. Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, Savaraj N (2008) Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des 14(11): 1049-1057 (Pubitemid 351982554)
12. Feun LG, You M, Wu C, Wangpaichitr M, Kuo MT, Marini A, Jungbluth A, Savaraj N (2010) Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in metastatic melanoma (MM). J Clin Oncol (Meeting Abstracts) 28(15-suppl): 8528-852
13. Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, Beneduce G, Castello G, De Rosa V, Petrillo A, Ascierto PA, Curley SA, Izzo F (2010) Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 28(13): 2220-2226
14. Gong H, Zolzer F, von Recklinghausen G, Havers W, Schweigerer L (2000) Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis. Leukemia 14(5): 826-829 (Pubitemid 30235059)
15. Gong H, Zolzer F, von Recklinghausen G, Rossler J, Breit S, Havers W, Fotsis T, Schweigerer L (1999) Arginine deiminase inhibits cell proliferation by arresting cell cycle and inducing apoptosis. Biochem Biophys Res Commun 261(1): 10-14 (Pubitemid 29371610)
16. Holtsberg FW, Ensor CM, Steiner MR, Bomalaski JS, Clark MA (2002) Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J Control Release 80(1-3): 259-271 (Pubitemid 34273764)
17. Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V, Cremona F, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA, Ng C, Curley SA (2004) Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 22(10): 1815-1822 (Pubitemid 41095171)
18. Jungbluth AA, Tassello J, Frosina D, Hanson N, Ritter G, Wu B-W, Old LJ (2010) Expression pattern of Argininosuccinate-Synthetase (ASS) in normal and tumor tissue as a marker for susceptibility to Arginine-Deiminase (ADI) therapy. Mod Pathol 23(Suppl 1): 387A
19. Kim JH, Yu YS, Kim DH, Min BH, Kim KW (2007) Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma. Oncol Rep 18(6): 1373-1377
20. Kim RH, Bold RJ, Kung HJ (2009a) ADI, autophagy and apoptosis: metabolic stress as a therapeutic option for prostate cancer. Autophagy 5(4): 567-568
21. Kim RH, Coates JM, Bowles TL, McNerney GP, Sutcliffe J, Jung JU, Gandour-Edwards R, Chuang FY, Bold RJ, Kung HJ (2009b) Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res 69(2): 700-708
22. Kobayashi E, Masuda M, Nakayama R, Ichikawa H, Satow R, Shitashige M, Honda K, Yamaguchi U, Shoji A, Tochigi N, Morioka H, Toyama Y, Hirohashi S, Kawai A, Yamada T (2010) Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma. Mol Cancer Ther 9(3): 535-544
23. Kondo Y, Kanzawa T, Sawaya R, Kondo S (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5(9): 726-734 (Pubitemid 41486365)
24. Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13(6): 472-482 (Pubitemid 351766797)
25. Lu S, Hoestje SM, Choo E, Epner DE (2003) Induction of caspasedependent and-independent apoptosis in response to methionine restriction. Int J Oncol 22(2): 415-420
26. Ni Y, Schwaneberg U, Sun ZH (2008) Arginine deiminase, a potential antitumor drug. Cancer Lett 261(1): 1-11
27. Nicholson LJ, Smith PR, Hiller L, Szlosarek PW, Kimberley C, Sehouli J, Koensgen D, Mustea A, Schmid P, Crook T (2009) Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer 125(6): 1454-1463
28. Noh EJ, Kang SW, Shin YJ, Choi SH, Kim CG, Park IS, Wheatley DN, Min BH (2004) Arginine deiminase enhances dexamethasone-induced cytotoxicity in human T-lymphoblastic leukemia CCRF-CEM cells. Int J Cancer 112(3): 502-508 (Pubitemid 39390617)
29. Ott PA, Carvajal RD, Pandit-Taskar N, Jungbluth AA, Hoffman E, Venhaus R, Pan L, Old L, Pavlick AC, Wolchok JD (2009) Phase I/II study of arginine deiminase (ADI-PEG 20) in patients with advanced malignant melanoma (MM). J Clin Oncol (Meeting Abstracts) 27(15S): 9030-903
30. Riccardi C, Nicoletti I (2006) Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 1(3): 1458-1461
31. Rodriguez E, Lilenbaum RC (2010) Small cell lung cancer: past, present, and future. Curr Oncol Rep 12(5): 327-334
32. Savaraj N, You M, Wu C, Wangpaichitr M, Kuo MT, Feun LG (2010) Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma. Curr Mol Med 10(4): 405-412
33. Shen LJ, Beloussow K, Shen WC (2006) Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase. Cancer Lett 231(1): 30-35 (Pubitemid 41779450)
34. Shen LJ, Lin WC, Beloussow K, Shen WC (2003) Resistance to the antiproliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase. Cancer Lett 191(2): 165-170 (Pubitemid 36255601)
35. Shen LJ, Shen WC (2006) Drug evaluation: ADI-PEG-20-a PEGylated arginine deiminase for arginine-auxotrophic cancers. Curr Opin Mol Ther 8(3): 240-248
36. Steiger-Barraissoul S, Rami A (2009) Serum deprivation induced autophagy and predominantly an AIF-dependent apoptosis in hippocampal HT22 neurons. Apoptosis 14(11): 1274-1288
37. Sugimura K, Ohno T, Kusuyama T, Azuma I (1992) High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro. Melanoma Res 2(3): 191-196
38. Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP, Rudd RM, Balkwill FR, Fennell DA (2006) In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 12(23): 7126-7131 (Pubitemid 44974513)
39. Takaku H, Takase M, Abe S, Hayashi H, Miyazaki K (1992) In vivo antitumor activity of arginine deiminase purified from Mycoplasma arginini. Int J Cancer 51(2): 244-249
40. Tennant DA, Duran RV, Gottlieb E (2010) Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10(4): 267-277
41. Tsai WB, Aiba I, Lee SY, Feun L, Savaraj N, Kuo MT (2009) Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1 alpha/Sp4. Mol Cancer Ther 8(12): 3223-3233
42. Yang TS, Lu SN, Chao Y, Sheen IS, Lin CC, Wang TE, Chen SC, Wang JH, Liao LY, Thomson JA, Wang-Peng J, Chen PJ, Chen LT (2010) A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer 103(7): 954-960
43. Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH, Kim JH, Park IS, Yoon DK, Min BH (2007) Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer 120(4): 897-905